ABSTRACT Hemoglobin Q-India (alpha) 
INTRODUCTION
The molecular characterization of Hemoglobin variants is usually conducted at two levels. The first level involves gel electrophoresis or cation exchange high performance liquid chromatography (HPLC) while the second level of analysis engages Mass Spectrometry (MS) (1, 2) and/or DNA sequencing (1) . The combination of liquid chromatography and Electrospray ionization Mass Spectrometry (LC-ESI-MS) (3) and DNA sequencing analysis are complementary techniques, with the latter usually being used to confirm deductions based upon mass spectrometric analysis.
Hemoglobin Q is a rare alpha chain variant first described by Vella et al (4) in association with D-Thalassemia in a Chinese family. The first case of HbQ-India was reported by Sukumaran (5) in 1972 in a Sindhi family with associated E-Thalassemia and later by Desai (6) . The present study describes the HPLC and molecular findings of HbQ hemoglobinopathy with a concomitant E-Thalassemia case from a 22year old lady who hailed from the state of Uttar Pradesh in North India was referred for comprehensive hematologic investigation, as part of prenatal check up to Manipal Hospital, Bangalore. The work reported here describes the molecular characterization of the variations on the Hb alpha and beta chains.
MATERIALS AND METHODS
Blood sample collected in EDTA tube was analyzed for a routine blood count using Sysmex XT 1800i Hematology analyzer. For Hemoglobin variant analysis a Biorad D10 HPLC instrument was used as per standard procedures. From the patient blood sample, plasma and buffy coat was aspirated away following centrifugation and the packed cells then washed with 0.9% NaCl. The washed cells were lysed with ice cold distilled water and the hemolysate centrifuged at 12880 xg for 10 minutes to remove the erythrocyte membranes. The clear supernatant was diluted 100 times with distilled water prior to Mass Spectrometric analysis.
Enzymatic digestion of hemoglobin was performed using Trypsin (TPCK treated). The digested sample was fractionated through a C18 reverse phase column. Fractions were collected and concentrated in a Speed Vac system and spotted onto a MALDI plate for MS analysis. MALDI Mass spectra were obtained on trypsin digested sample using an Ultraflex MALDI-TOF/TOF Mass spectrometer (Bruker Daltonics), using 200-ns time delay and a 25 KV accelerating voltage in positive ion mode. The system utilizes a 50-Hz pulsed nitrogen LASER , emitting at 337 nm. D-cyano-4-hydroxy cinnamic acid was used as a matrix.
Genomic DNA was extracted from the blood sample using the DNEasy kit from Qiagen. Based on MS data, HbQ-India mutation specific primers were used to amplify DNA using Amplification Refractory Mutation System (ARMS) PCR.
The
ARMS primer sequence used was 5' -CACGTGCGCCACGGCGTTTGGTCAGCGCGAG-3' along with a common primer 5' -CTGGTCCCCACAGACTCAGA -3' . The common reverse primer used was 5' AGGCCCAAGGGGCAAGAAGCAT 3' which produced a mutation specific PCR product of 370bp with the ARMS primer and a control band of 766bp with the common primer. PCR reactions were conducted on a PTC-100 Peltier Thermal cycler (M.J.Research) using 50 ul reactions including 5 ul of DNA template. The reaction conditions were: Initial precycling hold at 94°C for 2min, Thermocycling : 94°C denaturation for 45 secs, annealing at 54°C for 45secs, 72°C for 45secs (30cycles), and final extension at 72°C for 2 mins. Sequencing of PCR product were conducted using ABI Prism Big Dye Terminator technology from Applied Biosystems, USA to confirm the mutation.
A screen for beta chain mutation(s) was conducted using the E-globin StripAssay SEA (ViennaLab Diagnostics GmbH). The kit follows a PCR based reverse dot blot hybridization (RDBH) protocol that simultaneously screens for 22 mutations covering >90% of the E-globin defects found and reported in Southeast Asia. Biotinylated primer products were detected using streptavidin alkaline phosphatase and colour substrates. The conditions for the PCR reaction and protocol for the RBDH assays were conducted following instructions from the kit.
RESULTS
The examination of blood in a pre-natal workup from a patient from North India presented an anomalous blood picture. Based on the hematological data, the patient had Hb levels of 12.7gm% and MCV of 61.8 fl. Peripheral smears showed a mildly hypochromic and microcytic blood picture. Biorad D10 HPLC profiles (reverse phase HPLC) (Fig1) showed an intense peak at 4.46 min assigned as unknown and HbA 2 levels of 5.1% at 3.21 min.
To investigate the nature of the large unknown peak detected by HPLC, mass spectral analysis was conducted. Primary mass assignments of deconvoluted LC/ESI-MS spectral data (Fig 2, upper right) revealed the presence of a peptide with a 
Identification of Hemoglobin Q:
To further characterize the suspected HbQ variant, hemoglobin prepartions from the patient along with a normal control was subject to tryptic digestion followed by MALDI-MS. The HPLC profile of tryptic digest is shown in (Fig 3a) , along with the MS spectra of the tryptic peptide finger print of HbQ is shown in (Fig 3b) . Comparisons of the MALDI-MS spectra of tryptic digests for the normal Hb sample and putative HbQ, reveal a tryptic fragment with an m/z value of 2997.3 (Fig 4) . In the case of the variant sample, an additional peak is detected at m/z 3019.3 which corresponds to the 22Da increase in mass noted above.
The tryptic fragment at positions 62 to 90 would have a normal mass of of 2997.3 while a single change from D to H in this fragemt would result in a mass of 3019.3 Da (Fig 5) . However, since the concerned fragment includes four Aspartate residues the question of which of these would have undergone the mutation required further investigation. Earlier reports have DNA sequence level characterization of HbQ: Given that the mass spectrometric analysis of tryptic fragments conducted above would not resolve the specific position of the Asp>His alteration from the fragment, a DNA based analysis of this region was conducted using two approaches. First, DNA preparations of peripheral blood isolated from the patient was subjected to molecular analysis by an amplification refractory mutation system PCR (ARMS-PCR) (10) . In this case, an HbQIndia specific primer was used to see if the site of the alteration was at this location. The predicted 370 bp fragment resulting from the PCR reaction confirmed that the mutation indeed was HbQ-India (Fig 6a) . The ARMS-PCR was then further cross verified by sequencing the concerned region. Sequencing electropherograms clearly demonstrated the specific location of the mutation as HbQ-India and further showed that the codon GAC encoding Aspartic acid (D) was mutated to codon CAC encoding for Histidine (H) (Fig 6b) . The overlapping peaks of about equal intensity for both G and C at the point of the mutation reflect the heterozygosity of the mutation with both the normal and mutant allele being present in the genomic DNA of the patient.
Since the HbA 2 level and blood cell indices of the patient indicated the concomitant presence of beta thalassemia trait, a screening kit from Vienna Labs was used for identifying any beta chain mutation. The kit uses E-globin gene specific primers in a multiplex PCR reaction and the amplified product is subsequently analysed to investigate if any of the 22 known common mutations that have been reported in the South East Asian region has been amplified in a reverse dot blot hybridization strip assay.
As seen in (Fig7) the amplification products selectively hybridized to the IVS 1-1 band (arrow) among the other 22 mutations in its panel confirming that the patient harbours a E-thalessemia mutation, more specifically IVS 1-1 [G > T]. The presence of positive bands for the entire lower wild type panel in the assay strip further indicates that this mutation is present in the heterozygous state.
DISCUSSION
HbQ-India variant is an alpha chain variant due to structural mutation. The other molecular variants identified and documented have been HbQ-Thailand and HbQ-Iran. Since HbQ-India is a silent variant, in this case its association with beta thalassemia trait IVS 1-1[G>T] also has not produced any clinical abnormality. Based on earlier references HbQIndia with presence of beta thalassemia trait though have been reported using electrophoresis, HPLC (11) and ARMS -PCR techniques, our emphasis has been on using Mass Spectrometry with RDBH and DNA sequencing at arriving at a definitive diagnosis.
Electro spray ionization Mass Spectrometry provides a rapid method of identifying structural hemoglobin variants, and its characterization. Specific sequence level mutations are also done using MS-MS fragmentation approaches, though in this case we followed a sequencing and molecular biology approach. In the process of identifying the site of mutation, it is evident that MS and DNA sequencing are complementary techniques. The Vienna Lab E-globin strip can be used for in vitro amplification of E-globin gene sequences, and the subsequent detection of nearly twenty two mutations based on reverse hybridization technique. In case of this patient due to presence of an alpha chain variant along with 
